Q-omics provides the consensus-scored SNORD63B profile across patient tissues and cancer cell-line models. SNORD63B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORD63B is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, SNORD63B RNA expression shows 18,255 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, and THYM as cancer lineages where SNORD63B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD63B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD63B survival associations across molecular data types. SNORD63B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD63B RNA expression–survival associations across cancer types. High SNORD63B expression shows unfavorable associations in KICH, KIRC, THCA, COAD and UVM, but favorable associations in HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORD63B RNA expression.
This table summarizes SNORD63B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD63B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD63B shows lower tumor expression in BRCA and UCEC and higher tumor expression in KICH, KIRC, CHOL and READ. The KICH box plot shows higher SNORD63B RNA expression in tumor versus normal tissue (log2 FC = +1.332, t-test p < 0.001).
This table shows molecular features associated with SNORD63B in patient tissues and cancer cell lines. In patient samples, SNORD63B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
